n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Chronic Disease in 5 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epileptic seizures drive expression of the blood-brain barrier efflux transporter P-glycoprotein via a glutamate/cyclooxygenase-2 mediated signalling pathway." | 1.36 | COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. ( Aronica, E; Edelbroek, PM; Gorter, JA; Holtman, L; Pekcec, A; Potschka, H; Schlichtiger, J; van Vliet, EA; Zibell, G, 2010) |
| "In vehicle-treated rats, gastric ulcers healed progressively and at day 14 the healing was completed, accompanied by a significant rise in the GBF at ulcer margin." | 1.31 | Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. ( Brzozowski, T; Drozdowicz, D; Hahn, EG; Konturek, PC; Konturek, SJ; Pajdo, R; Ptak, A; Sliwowski, Z, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Vliet, EA | 1 |
| Zibell, G | 1 |
| Pekcec, A | 1 |
| Schlichtiger, J | 1 |
| Edelbroek, PM | 1 |
| Holtman, L | 1 |
| Aronica, E | 1 |
| Gorter, JA | 1 |
| Potschka, H | 1 |
| Poplawski, C | 1 |
| Sosnowski, D | 1 |
| Szaflarska-Popławska, A | 1 |
| Sarosiek, J | 1 |
| McCallum, R | 1 |
| Bartuzi, Z | 1 |
| Cong, P | 1 |
| Pricolo, V | 1 |
| Biancani, P | 1 |
| Behar, J | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Sliwowski, Z | 1 |
| Pajdo, R | 1 |
| Drozdowicz, D | 1 |
| Ptak, A | 1 |
| Hahn, EG | 1 |
| Kim, TI | 1 |
| Lee, YC | 1 |
| Lee, KH | 1 |
| Han, JH | 1 |
| Chon, CY | 1 |
| Moon, YM | 1 |
| Kang, JK | 1 |
| Park, IS | 1 |
5 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Chronic Disease
| Article | Year |
|---|---|
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2010 |
Role of bile acids, prostaglandins and COX inhibitors in chronic esophagitis in a mouse model.
Topics: Animals; Bile Acids and Salts; Chronic Disease; Cyclooxygenase Inhibitors; Dinoprostone; Disease Mod | 2006 |
Abnormalities of prostaglandins and cyclooxygenase enzymes in female patients with slow-transit constipation.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Chronic Disease; Colon; Constipation; Cyclooxy | 2007 |
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase 1; Cycloo | 2001 |
Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Division; Chronic Disease; Cycloox | 2001 |